Clinical Cases in HER2+ Breast Cancer

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.